Viking Therapeutics: Q3 Earnings Report Loads A Barrage Of Catalysts

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been over five months since my previous Viking Therapeutics (NASDAQ: VKTX ) article , where I laid out a case for Viking Therapeutics as a prime acquisition target thanks to their impressive pipeline targeting obesity, NASH, X-ALD, and sarcopenia. ...